Anamorelin

Drug Profile

Anamorelin

Alternative Names: Anamorelin HCl; Anamorelin hydrochloride; ONO-7643; RC-1291; ST-1291

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Helsinn Therapeutics; Ono Pharmaceutical
  • Class Appetite stimulants; Piperidines; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anorexia; Cachexia
  • Phase II Fatigue

Most Recent Events

  • 08 Feb 2017 Phase-II clinical trials in cancer Fatigue in USA (PO) (NCT03035409)
  • 26 Jan 2017 M.D. Anderson Cancer Center and Helsinn Healthcare plan a phase II trial for Cachexia in USA (PO) (NCT03035409)
  • 14 Nov 2016 Ono pharmaceuticals plans a phase III trial for Cachexia in Japan (JapicCTI-163426)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top